Im­prov­ing the lives of Type 1 di­a­betes pa­tients with safer mod­ern in­sulin

Hindustan Times ST (Jaipur) - Hindustan Times (Jaipur) - City - - Front Page - HTC

Silently brew­ing among In­dia’s huge pop­u­la­tion of di­a­bet­ics is a heart­break­ing story of nearly 1.5 mil­lion pa­tients below 20 with Type 1 di­a­betes. Dr Suren­dra Ku­mar Sharma, en­docri­nol­o­gist, Jaipur, says, “Those suf­fer­ing from Type 1 di­a­betes are not reg­u­lar pa­tients, who can be treated with oral medicines. They re­quire in­sulin in­jec­tions mul­ti­ple times a day just to sur­vive. Even with ad­vances in tech­nol­ogy and ac­cess to newer, safer, and more ef­fec­tive in­sulin, called mod­ern in­sulin (analogs), the cost of these in­sulin al­ter­na­tives is high com­pared to older in­sulin.” The choice such pa­tients and their fam­i­lies have is to con­tinue to bear the enor­mous cost of mod­ern safe in­sulin ev­ery day or to suf­fer from side ef­fects of older and tra­di­tional in­sulin variants. Since these pa­tients are very young, the eco­nomic im­pact on these fam­i­lies is three to four times the im­pact on other di­a­betes pa­tients di­ag­nosed later in life and man­aged through oral medicines. But now, few en­ter­pris­ing In­dian firms with a global ap­proach have taken on this hu­man-eco­nomic cost chal­lenge of in­creas­ing ac­cess to safer mod­ern in­sulin at 50% of the cost of in­no­va­tor brands. Dr Sharma says, “These com­pa­nies not only save lives by of­fer­ing in­sulin at lower cost but also en­sure that the pa­tients stay on ther­apy so that com­pli­ca­tions are avoided.”

Dis­claimer: The ve­rac­ity of any health claim made in the above ar­ti­cle is the re­spon­si­bil­ity of the con­cerned hos­pi­tal/doc­tor.


Dr Suren­dra Ku­mar Sharma, en­docri­nol­o­gist, Jaipur

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.